Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline
China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its...
Simcere’s Trilaciclib Wins NMPA Approval for Chemotherapy Myeloprotection
Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...
China’s 2021 Healthcare Report Shows Rising Life Expectancy, Increased Medical Spending
China’s National Health Commission (NHC) released the “Healthcare Statistical Communique 2021,” revealing increased healthcare spending,...
Sinopharm Biotec and Ganzhou Government Partner on Medical Testing and Biotech R&D
Sinopharm China National Biotec Group Co., Ltd (CNBG) announced a strategic partnership with the government...
Basecare Medical and Haier Biomedical Partner on IVF Cryopreservation Tech
China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) announced a strategic partnership with...
Huadong Medicine’s Biosimilar Victoza (Liraglutide) Accepted for NMPA Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
CorrectSequence Therapeutics’ tBE Tech Wins USPTO Patent for Gene Editing
Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United...
Zai Lab’s Efgartigimod NDA Accepted by NMPA for Myasthenia Gravis
Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the National Medical Products Administration (NMPA)...
Overland ADCT BioPharma Doses First Patient in Zynlonta’s Phase III LOTIS-5 Study for DLBCL
Overland ADCT BioPharma (CY) Ltd, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC...
Triastek Partners with Eli Lilly to Explore 3D Printing for GI Drug Delivery
China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...
Zhejiang Medicine’s ARX305 ADC Receives Clinical Trial Approval for CD70-Positive Cancers
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...
GenScript ProBio Partners with ACT Therapeutics on CAR-T Cell Therapy Development
GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding...
Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment
Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...
NMPA Reclassifies Glucosamine Sulfate to OTC, Mandates Label Revisions
China’s National Medical Products Administration (NMPA) announced that potassium glucosamine sulfate has been reclassified from...
China’s JPO Launches VBP Round for Orthopedic Spine Consumables
China’s Joint Procurement Office (JPO) announced plans on July 11 to conduct a volume-based procurement...
HutchMed’s Orpathys-Tagrisso Combo Shows Promise in NSCLC at WCLC
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...
Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...
Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study
Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...
China’s 7th VBP Round Yields 65.5% Drug Price Cuts, Foreign Firms Secure Bids
China’s 7th national volume-based procurement (VBP) round concluded with winning bids averaging a 65.5% price...
CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab
The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...